Advertisement

Muscle Weakness and Fever

  • Piyush Kumar
  • Anupam Das
Chapter

Abstract

  • Presence of the characteristic heliotrope rash on eyelids, violaceus rash in sun exposed areas and the Gottron papules on knuckles, is necessary for the diagnosis of juvenile dermatomyositis

  • Symptomatic lung diseases and association with underlying malignancy are more common in adult dermatomyositis but not juvenile dermatomyositis

  • Calcinosis cutis and cutaneous ulcerations are seen up to 30% cases of juvenile dermatomyositis

  • Intravenous immunoglobulin, cyclophosphamide, and mycophenolate mofetil are first-line immunosuppressive therapy in juvenile dermatomyositis

  • Intensive physiotherapy and strict photoprotection are essential ellements in treatment of dermatomyositis

Keywords

Juvenile dermatomyositis Gottron papules Heliotrope rash Calcinosis cutis 

References

  1. 1.
    Pachman LM, Lipton R, Ramsey-Goldman R, Shamiyeh E, Abbott K, Mendez EP, Dyer A, Curdy DM, Vogler L, Reed A, Cawkwell G, Zemel L, Sandborg C, Rivas-Chacon R, Hom C, Ilowite N, Gedalia A, Gitlin J, Borzy M. History of infection before the onset of juvenile dermatomyositis: results from the National Institute of Arthritis and Musculoskeletal and Skin Diseases Research Registry. Arthritis Rheum. 2005;53(2):166–72.CrossRefGoogle Scholar
  2. 2.
    Boccaletti V, Di Nuzzo S, Feliciani C, Fabrizi G, Pagliarello C. An update on juvenile dermatomyositis. G Ital Dermatol Venereol. 2014;149(5):519–24.PubMedGoogle Scholar
  3. 3.
    Rider LG, Lachenbruch PA, Monroe JB, Ravelli A, Cabalar I, Feldman BM, Villalba ML, Myones BL, Pachman LM, Rennebohm RM, Reed AM, Miller FW. Damage extent and predictors in adult and juvenile dermatomyositis and polymyositis as determined with the myositis damage index. Arthritis Rheum. 2009;60(11):3425–35.CrossRefGoogle Scholar
  4. 4.
    Tansley SL, McHugh NJ, Wedderburn LR. Adult and juvenile dermatomyositis: are the distinct clinical features explained by our current understanding of serological subgroups and pathogenic mechanisms? Arthritis Res Ther. 2013;15(2):211.CrossRefGoogle Scholar
  5. 5.
    Ravelli A, Trail L, Ferrari C, Ruperto N, Pistorio A, Pilkington C, Maillard S, Oliveira SK, Sztajnbok F, Cuttica R, Beltramelli M, Corona F, Katsicas MM, Russo R, Ferriani V, Burgos-Vargas R, Magni-Manzoni S, Solis-Valleoj E, Bandeira M, Zulian F, Baca V, Cortis E, Falcini F, Alessio M, Alpigiani MG, Gerloni V, Saad-Magalhaes C, Podda R, Silva CA, Lepore L, Felici E, Rossi F, Sala E, Martini A. Long-term outcome and prognostic factors of juvenile dermatomyositis: a multinational, multicenter study of 490 patients. Arthritis Care Res. 2010;62(1):63–72.CrossRefGoogle Scholar
  6. 6.
    Martin N, Li CK, Wedderburn LR. Juvenile dermatomyositis: new insights and new treatment strategies. Ther Adv Musculoskelet Dis. 2012;4(1):41–50.CrossRefGoogle Scholar
  7. 7.
    Enders FB, Bader-Meunier B, Baildam E, Constantin T, Dolezalova P, Feldman BM, Lahdenne P, Magnusson B, Nistala K, Ozen S, Pilkington C, Ravelli A, Russo R, Uziel Y, van Brussel M, van der Net J, Vastert S, Wedderburn LR, Wulffraat N, McCann LJ, van Royen-Kerkhof A. Consensus-based recommendations for the management of juvenile dermatomyositis. Ann Rheum Dis. 2017;76(2):329–40.CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2020

Authors and Affiliations

  • Piyush Kumar
    • 1
  • Anupam Das
    • 2
  1. 1.Department of DermatologyKatihar Medical CollegeKatiharIndia
  2. 2.Department of DermatologyKPC Medical CollegeKolkataIndia

Personalised recommendations